# Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

> **NCT00003345** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 35 (estimated)

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00003345
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-10
- **Primary completion:** 2001-10
- **Final completion:** 2001-10
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2013-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003345, "Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00003345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*